Viewing Study NCT00560794

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2026-02-05 @ 10:43 PM
Study NCT ID: NCT00560794
Status: COMPLETED
Last Update Posted: 2015-01-26
First Post: 2007-11-19
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Sponsor: Amgen Research (Munich) GmbH
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Lymphoblastic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Minimal Residual Disease View
None adult ALL View
None immunotherapeutic treatment View
None anti-CD19 bispecific antibody derivative View
None Blinatumomab View
None MT103 View